Pinnacle Wealth Planning Services Inc. Buys 1,302 Shares of Gilead Sciences, Inc. $GILD

Pinnacle Wealth Planning Services Inc. grew its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 23.0% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 6,953 shares of the biopharmaceutical company’s stock after purchasing an additional 1,302 shares during the quarter. Pinnacle Wealth Planning Services Inc.’s holdings in Gilead Sciences were worth $771,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in GILD. GoalVest Advisory LLC boosted its position in Gilead Sciences by 7,566.7% during the 2nd quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 227 shares during the period. Activest Wealth Management raised its stake in shares of Gilead Sciences by 2,837.5% during the first quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 227 shares during the last quarter. Harbor Asset Planning Inc. purchased a new stake in shares of Gilead Sciences during the second quarter worth about $27,000. Putney Financial Group LLC grew its stake in shares of Gilead Sciences by 53.4% in the second quarter. Putney Financial Group LLC now owns 270 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 94 shares during the last quarter. Finally, Colonial Trust Advisors grew its stake in shares of Gilead Sciences by 304.3% in the first quarter. Colonial Trust Advisors now owns 283 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 213 shares during the last quarter. Institutional investors own 83.67% of the company’s stock.

Insider Buying and Selling

In related news, CEO Daniel Patrick O’day sold 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, October 28th. The stock was sold at an average price of $119.39, for a total value of $1,193,900.00. Following the sale, the chief executive officer owned 581,203 shares in the company, valued at $69,389,826.17. This represents a 1.69% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction on Wednesday, October 15th. The shares were sold at an average price of $118.08, for a total value of $295,200.00. Following the transaction, the chief financial officer owned 157,055 shares of the company’s stock, valued at $18,545,054.40. The trade was a 1.57% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 94,646 shares of company stock valued at $11,311,286. 0.27% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the company. Weiss Ratings reiterated a “buy (b)” rating on shares of Gilead Sciences in a report on Wednesday, October 8th. Royal Bank Of Canada raised their price target on Gilead Sciences from $100.00 to $105.00 and gave the stock a “sector perform” rating in a research note on Friday, October 31st. Needham & Company LLC lifted their price target on shares of Gilead Sciences from $133.00 to $140.00 and gave the company a “buy” rating in a report on Thursday, November 13th. BMO Capital Markets upped their price objective on shares of Gilead Sciences from $130.00 to $135.00 and gave the stock an “outperform” rating in a report on Monday, October 20th. Finally, Citigroup raised their target price on shares of Gilead Sciences from $125.00 to $135.00 and gave the stock a “buy” rating in a research report on Wednesday, October 8th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Gilead Sciences presently has an average rating of “Moderate Buy” and an average price target of $129.13.

Gilead Sciences Stock Performance

Shares of Gilead Sciences stock opened at $124.09 on Tuesday. Gilead Sciences, Inc. has a 12 month low of $86.08 and a 12 month high of $127.68. The firm has a market capitalization of $153.96 billion, a P/E ratio of 24.72, a P/E/G ratio of 0.81 and a beta of 0.32. The company has a current ratio of 1.32, a quick ratio of 1.15 and a debt-to-equity ratio of 1.13. The business has a fifty day simple moving average of $117.61 and a two-hundred day simple moving average of $113.02.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.16 by $0.31. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The company had revenue of $7.77 billion during the quarter, compared to analyst estimates of $7.42 billion. During the same period last year, the business earned $2.02 EPS. Gilead Sciences’s quarterly revenue was up 3.0% compared to the same quarter last year. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. On average, equities analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 30th. Stockholders of record on Monday, December 15th will be issued a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a dividend yield of 2.5%. The ex-dividend date is Monday, December 15th. Gilead Sciences’s dividend payout ratio (DPR) is presently 48.99%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.